American Century Companies Inc. Sells 225,820 Shares of Sage Therapeutics, Inc. (NASDAQ:SAGE)

American Century Companies Inc. cut its holdings in shares of Sage Therapeutics, Inc. (NASDAQ:SAGE - Free Report) by 67.9% in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 106,792 shares of the biopharmaceutical company's stock after selling 225,820 shares during the quarter. American Century Companies Inc. owned 0.17% of Sage Therapeutics worth $580,000 at the end of the most recent quarter.

A number of other large investors also recently made changes to their positions in SAGE. State Street Corp boosted its holdings in Sage Therapeutics by 18.2% in the third quarter. State Street Corp now owns 2,926,239 shares of the biopharmaceutical company's stock worth $21,127,000 after purchasing an additional 451,377 shares in the last quarter. Connor Clark & Lunn Investment Management Ltd. raised its stake in shares of Sage Therapeutics by 157.9% in the 4th quarter. Connor Clark & Lunn Investment Management Ltd. now owns 169,057 shares of the biopharmaceutical company's stock valued at $918,000 after acquiring an additional 103,495 shares in the last quarter. Charles Schwab Investment Management Inc. lifted its holdings in Sage Therapeutics by 10.7% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 452,193 shares of the biopharmaceutical company's stock worth $3,265,000 after purchasing an additional 43,617 shares during the last quarter. Thrivent Financial for Lutherans boosted its position in Sage Therapeutics by 108.7% during the fourth quarter. Thrivent Financial for Lutherans now owns 74,625 shares of the biopharmaceutical company's stock worth $405,000 after purchasing an additional 38,876 shares during the period. Finally, Amundi bought a new position in shares of Sage Therapeutics in the fourth quarter valued at approximately $166,000. Institutional investors and hedge funds own 99.22% of the company's stock.

Remove Ads

Sage Therapeutics Price Performance

Shares of SAGE traded down $0.19 during trading hours on Wednesday, hitting $7.35. The stock had a trading volume of 353,769 shares, compared to its average volume of 1,248,334. The stock has a market capitalization of $451.89 million, a price-to-earnings ratio of -1.12 and a beta of 0.48. The company's fifty day moving average is $7.46 and its two-hundred day moving average is $6.71. Sage Therapeutics, Inc. has a 52 week low of $4.62 and a 52 week high of $15.74.

Sage Therapeutics (NASDAQ:SAGE - Get Free Report) last issued its quarterly earnings data on Tuesday, February 11th. The biopharmaceutical company reported ($1.56) earnings per share for the quarter, missing the consensus estimate of ($1.54) by ($0.02). Sage Therapeutics had a negative return on equity of 68.18% and a negative net margin of 971.50%. Equities analysts predict that Sage Therapeutics, Inc. will post -3.52 EPS for the current fiscal year.

Analyst Ratings Changes

A number of research firms recently issued reports on SAGE. Bank of America assumed coverage on shares of Sage Therapeutics in a research note on Tuesday, March 11th. They issued an "underperform" rating and a $5.00 target price on the stock. Wedbush reaffirmed a "neutral" rating and issued a $6.00 target price on shares of Sage Therapeutics in a report on Wednesday, February 12th. Needham & Company LLC reissued a "hold" rating on shares of Sage Therapeutics in a research report on Wednesday, February 12th. Canaccord Genuity Group dropped their target price on shares of Sage Therapeutics from $9.00 to $8.00 and set a "hold" rating on the stock in a research report on Wednesday, February 12th. Finally, Scotiabank reduced their price target on shares of Sage Therapeutics from $14.00 to $12.00 and set a "sector outperform" rating for the company in a report on Wednesday, February 12th. Three research analysts have rated the stock with a sell rating, fifteen have given a hold rating and two have issued a buy rating to the stock. According to MarketBeat, the stock has a consensus rating of "Hold" and an average price target of $8.81.

Sage Therapeutics Profile

Sage Therapeutics, Inc, a biopharmaceutical company, develops and commercializes brain health medicines. Its product candidates include ZULRESSO, a CIV injection for the treatment of postpartum depression (PPD) in adults; and ZURZUVAE, a neuroactive steroid, a positive allosteric modulator of GABAA receptors, targeting both synaptic and extrasynaptic GABAA receptors, for the treatment of postpartum depression.